CD20-targeted CAR-T therapy for relapsed/refractory B-cell hematological malignancies

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026350

Enrollment

Unknown

Registered

2019-10-01

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell hematological malignancies

Interventions

single arm:CD20 CAR-T treatment

Eligibility

Sex/Gender

Male

Age

5 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1)CD20 positive; 2)relapsed/refactory; 3)survival time of more than 3 months.

Exclusion criteria

Exclusion criteria: 1)infection; 2)HIV positive; 3)pregnancy.

Design outcomes

Primary

Measure	Time frame
overall survival rate;CRS rate;	—

Secondary

Measure	Time frame
infection rate;pancytopenia rate;	—

Countries

China

Contacts

Public ContactHe Huang

The First Affiliated Hospital, School of Medicine, Zhejiang University

huanghe@zju.edu.cn+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026